ARVINAS, INC. - 8-K Filing
Arvinas reports Q3 2026 revenue of $0.5M and announces initiation of dosing for ARV-6723 Phase 1/2 trial. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ARVN
Read the full article at SEC EDGAR
Part of the story Pangaea Logistics Reports Record Q3 2026 Results Driven by Arctic Trade Strength (8 articles)